New insights into the Immune TME of adult-type diffuse gliomas
- PMID: 36226710
- PMCID: PMC9671594
- DOI: 10.1097/WCO.0000000000001112
New insights into the Immune TME of adult-type diffuse gliomas
Abstract
Purpose of review: Adult-type diffuse gliomas are highly heterogeneous tumors. Bulk transcriptome analyses suggested that the composition of the tumor microenvironment (TME) corresponds to genetic and clinical features. In this review, we highlight novel findings on the intratumoral heterogeneity of IDH-wildtype and IDH-mutant gliomas characterized at single-cell resolution, and emphasize the mechanisms shaping the immune TME and therapeutic implications.
Recent findings: Emergent evidence indicates that in addition to genetic drivers, epigenetic mechanisms and microenvironmental factors influence the glioma subtypes. Interactions between glioma and immune cells contribute to immune evasion, particularly in aggressive tumors. Spatial and temporal heterogeneity of malignant and immune cell subpopulations is high in recurrent gliomas. IDH-wildtype and IDH-mutant tumors display distinctive changes in their myeloid and lymphoid compartments, and D-2HG produced by IDH-mutant cells impacts the immune TME.
Summary: The comprehensive dissection of the intratumoral ecosystem of human gliomas using single-cell and spatial transcriptomic approaches advances our understanding of the mechanisms underlying the immunosuppressed state of the TME, supports the prognostic value of tumor-associated macrophages and microglial cells, and sheds light on novel therapeutic options.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Figures





Similar articles
-
Single-Cell Profiling and Proteomics-Based Insights Into mTORC1-Mediated Angio+TAMs Polarization in Recurrent IDH-Mutant Gliomas.CNS Neurosci Ther. 2025 Apr;31(4):e70371. doi: 10.1111/cns.70371. CNS Neurosci Ther. 2025. PMID: 40202138 Free PMC article.
-
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.Neuro Oncol. 2023 Feb 14;25(2):263-276. doi: 10.1093/neuonc/noac138. Neuro Oncol. 2023. PMID: 35609569 Free PMC article.
-
Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.Acta Neuropathol Commun. 2022 Feb 10;10(1):19. doi: 10.1186/s40478-022-01323-w. Acta Neuropathol Commun. 2022. PMID: 35144680 Free PMC article.
-
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Curr Opin Oncol. 2022 Nov 1;34(6):653-660. doi: 10.1097/CCO.0000000000000895. Epub 2022 Aug 24. Curr Opin Oncol. 2022. PMID: 36000367 Review.
-
Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.Front Immunol. 2022 Jun 13;13:914618. doi: 10.3389/fimmu.2022.914618. eCollection 2022. Front Immunol. 2022. PMID: 35769466 Free PMC article. Review.
Cited by
-
Characterization of growth arrest-specific transcript 5 and growth arrest-specific transcript 5-related m6A gene signature in glioma: An observational study.Medicine (Baltimore). 2024 Sep 27;103(39):e39414. doi: 10.1097/MD.0000000000039414. Medicine (Baltimore). 2024. PMID: 39331894 Free PMC article.
-
Identification of an Immune signature assisted prognosis, and immunotherapy prediction for IDH wildtype glioblastoma.J Cancer. 2024 Oct 21;15(19):6452-6467. doi: 10.7150/jca.100144. eCollection 2024. J Cancer. 2024. PMID: 39513108 Free PMC article.
-
Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign.Neuroradiology. 2024 Apr;66(4):521-530. doi: 10.1007/s00234-024-03297-z. Epub 2024 Feb 13. Neuroradiology. 2024. PMID: 38347151
-
Regulation of the brain tumor microenvironment by focused ultrasound.Mol Ther Oncol. 2025 May 14;33(2):200994. doi: 10.1016/j.omton.2025.200994. eCollection 2025 Jun 18. Mol Ther Oncol. 2025. PMID: 40520576 Free PMC article. Review.
-
Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. Cancers (Basel). 2024. PMID: 38539537 Free PMC article.
References
-
- Gimple RC, Yang K, Halbert ME, et al. . Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer 2022; 22:497–514. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials